US Patent

US12403182 — Liquid pharmaceutical formulations of PTH conjugates

Method of Use · Assigned to Ascendis Pharma Bone Diseases AS · Expires 2042-11-12 · 16y remaining

Vulnerability score 75/100 Vulnerable — likely target for IPR or design-around

What this patent protects

This patent protects a liquid pharmaceutical formulation that includes a PTH conjugate, a buffering agent, and an isotonicity agent.

USPTO Abstract

A liquid pharmaceutical formulation, wherein the pharmaceutical formulation comprises a PTH conjugate, a buffering agent, an isotonicity agent, a preservative and optionally an antioxidant and wherein the PTH conjugate comprises a PTH moiety that is covalently and reversibly conjugated to a water-soluble carrier moiety.

Drugs covered by this patent

Yorvipath (PALOPEGTERIPARATIDE) · Ascendis Pharma Bone

FDA Patent Use Codes

When a patent is method-of-use, FDA lists it once per applicable indication ("U-code"). Each U-code carves out a specific therapeutic use that generic filers must either license or design around.

Code	Description	Drug
`U-3982`	—	Yorvipath
`U-3982`	—	Yorvipath
`U-3982`	—	Yorvipath

Patent Metadata

Patent number: US12403182
Jurisdiction: US
Classification: Method of Use
Expires: 2042-11-12
Drug substance claim: No
Drug product claim: Yes
Assignee: Ascendis Pharma Bone Diseases AS
Source: FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.